Short Interest in Qualigen Therapeutics, Inc. (NASDAQ:QLGN) Decreases By 15.3%

Qualigen Therapeutics, Inc. (NASDAQ:QLGN) was the target of a significant drop in short interest during the month of February. As of February 28th, there was short interest totalling 75,300 shares, a drop of 15.3% from the February 13th total of 88,900 shares. Based on an average trading volume of 49,500 shares, the short-interest ratio is presently 1.5 days. Currently, 11.0% of the company’s shares are sold short.

Qualigen Therapeutics Trading Up 1.3 %

Qualigen Therapeutics stock opened at $3.10 on Tuesday. The business’s 50-day simple moving average is $3.55 and its 200 day simple moving average is $5.23. Qualigen Therapeutics has a 12-month low of $2.96 and a 12-month high of $29.44.

Qualigen Therapeutics Company Profile

Qualigen Therapeutics, Inc, a biotechnology company, focuses on the development and commercialization of novel therapeutic products for the treatment of cancer and infectious diseases. It offers FastPack, a patent-protected rapid, onsite immunoassay testing system. The company is developing QN-302 for the treatment of pancreatic ductal adenocarcinoma; QN-247, an oligonucleotide-based drug candidate to treat various nucleolin-expressing cancers, including liquid and solid tumors; QN-165, a drug candidate for the potential broad-spectrum treatment of infectious diseases, such as COVID-19; RAS-F, a small-molecule RAS oncogene protein-protein inhibitor that blocks RAS mutations and inhibits tumor formation; and selective target antigen removal system, a therapeutic device to remove circulating tumor cells, viruses, inflammation factors, and immune checkpoints.